Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease.
暂无分享,去创建一个
Michael Böhm | Helmut Schumacher | Salim Yusuf | Peter Sleight | Koon Teo | Thomas Unger | S. Yusuf | M. Böhm | U. Laufs | R. Schmieder | K. Teo | P. Sleight | T. Unger | H. Schumacher | Ulrich Laufs | Roland Schmieder | M. Böhm
[1] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[2] R. Balkrishnan,et al. Predictors of medication adherence in the elderly. , 1998, Clinical therapeutics.
[3] R. Herings,et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. , 2006, European heart journal.
[4] Matthew F. Muldoon,et al. Psychological and cognitive function: Predictors of adherence with cholesterol lowering treatment , 2004, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.
[5] D. Alter,et al. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. , 2007, JAMA.
[6] C. Viscoli,et al. Treatment adherence and risk of death after a myocardial infarction , 1990, The Lancet.
[7] S. Yusuf,et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.
[8] P. McDonnell,et al. Hospital Admissions Resulting from Preventable Adverse Drug Reactions , 2002, The Annals of pharmacotherapy.
[9] Alessandro Filippi,et al. Adherence to Antihypertensive Medications and Cardiovascular Morbidity Among Newly Diagnosed Hypertensive Patients , 2009, Circulation.
[10] S. Gutnikov,et al. From subgroups to individuals: general principles and the example of carotid endarterectomy , 2005, The Lancet.
[11] A. Wu,et al. Correlates and Predictors of Adherence to Highly Active Antiretroviral Therapy: Overview of Published Literature , 2002, Journal of acquired immune deficiency syndromes.
[12] P. Rothwell. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation , 2005, The Lancet.
[13] U. Laufs,et al. Strategies to improve drug adherence. , 2011, European heart journal.
[14] R. Cooper,et al. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. , 1988, Archives of internal medicine.
[15] J. Chan,et al. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial , 2006, BMJ : British Medical Journal.
[16] G. Huster,et al. Characterization of the precipitants of hospitalization for heart failure decompensation. , 1998, American journal of critical care : an official publication, American Association of Critical-Care Nurses.
[17] James M Wright,et al. Statin Adherence and Risk of Accidents: A Cautionary Tale , 2009, Circulation.
[18] L. Osterberg,et al. Adherence to medication. , 2005, The New England journal of medicine.
[19] S. Yusuf,et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Int , 2004, American heart journal.
[20] A. Chobanian. Impact of nonadherence to antihypertensive therapy. , 2009, Circulation.
[21] M. Pfeffer,et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial , 2005, The Lancet.
[22] S. Rössner,et al. Coronary Drug Project Research Group. , 1978, Atherosclerosis.
[23] W. Ahmad. Effect of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial: The Telmisartan Randomised Assessment Study in ACE intolerant subjects with cardiovascular Disease (TRANSCEND) , 2008 .
[24] S. Yusuf,et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials , 2006, The Lancet.
[25] D W Bates,et al. Practical approach to determining costs and frequency of adverse drug events in a health care network. , 2001, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[26] Ross T Tsuyuki,et al. A meta-analysis of the association between adherence to drug therapy and mortality , 2006, BMJ : British Medical Journal.
[27] S. Yusuf,et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial , 2008, The Lancet.
[28] Mary A Whooley,et al. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. , 2007, Archives of internal medicine.
[29] P Michael Ho,et al. Medication Adherence: Its Importance in Cardiovascular Outcomes , 2009, Circulation.
[30] J. Wittes,et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. , 1991, JAMA.